Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Hims & Hers Health Inc (HIMS)

Hims & Hers Health Inc (HIMS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Novo Nordisk Just Announced Wegovy Subscriptions. Does That Make NVO Stock a Buy?

Novo Nordisk (NVO) has multiple positive catalysts on the horzon, including its recent decision to offer subscriptions to Wegovy, its popular GLP-1 weight-loss drug. Still, given a forthcoming — and potentially huge — negative catalyst facing the company, investors may want to refrain from buying NVO stock for now.

What's going on with Novo Nordisk? Let's take a closer look.

Fundamentals

See More
  • Market Capitalization, $K 4,362,752
  • Shares Outstanding, K 227,939
  • Annual Sales, $ 2,348 M
  • Annual Income, $ 128,370 K
  • EBIT $ 106 M
  • EBITDA $ 163 M
  • 60-Month Beta 2.32
  • Price/Sales 1.93
  • Price/Cash Flow 23.71
  • Price/Book 8.33

Options Overview Details

View History
  • Implied Volatility 90.25% (-2.44%)
  • Historical Volatility 130.60%
  • IV Percentile 49%
  • IV Rank 40.62%
  • IV High 135.37% on 04/08/25
  • IV Low 59.38% on 12/31/25
  • Expected Move (DTE 6) 1.39 (7.28%)
  • Put/Call Vol Ratio 0.34
  • Today's Volume 139,131
  • Volume Avg (30-Day) 197,980
  • Put/Call OI Ratio 0.58
  • Today's Open Interest 1,059,681
  • Open Int (30-Day) 1,135,378
  • Expected Range 17.75 to 20.53

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $0.02
  • Number of Estimates 4
  • High Estimate $0.04
  • Low Estimate $-0.02
  • Prior Year $0.20
  • Growth Rate Est. (year over year) -90.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.21 +25.84%
on 03/06/26
27.54 -30.50%
on 03/11/26
+2.66 (+16.14%)
since 03/02/26
3-Month
13.74 +39.30%
on 02/24/26
36.45 -47.49%
on 01/07/26
-14.27 (-42.71%)
since 01/02/26
52-Week
13.74 +39.30%
on 02/24/26
70.43 -72.82%
on 07/31/25
-12.08 (-38.69%)
since 04/02/25

Most Recent Stories

More News
Hims & Hers Health Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Hims & Hers Health, Inc. - HIMS

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti , LLC (“KSF”), announces that KSF has commenced an investigation into...

HIMS : 19.14 (-3.53%)
Novo Nordisk Just Announced Wegovy Subscriptions. Does That Make NVO Stock a Buy?

Wegovy subscriptions may create interest, but there is a major threat looming for Novo Nordisk.

NVO : 36.98 (+1.37%)
HIMS : 19.14 (-3.53%)
LLY : 935.58 (-1.98%)
Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know

Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know

HIMS : 19.14 (-3.53%)
BMRN : 55.50 (-3.04%)
REGN : 761.85 (-1.98%)
MRNA : 49.20 (-1.66%)
BIIB : 177.34 (-3.50%)
Enovis, Neogen, Humana, LifeStance Health Group, and Hims & Hers Health Stocks Trade Down, What You Need To Know

Enovis, Neogen, Humana, LifeStance Health Group, and Hims & Hers Health Stocks Trade Down, What You Need To Know

ENOV : 22.64 (-3.12%)
HUM : 177.83 (+0.50%)
HIMS : 19.14 (-3.53%)
LFST : 6.31 (-0.94%)
NEOG : 9.41 (+0.21%)
2 Mooning Stocks on Our Buy List and 1 Facing Challenges

2 Mooning Stocks on Our Buy List and 1 Facing Challenges

HIMS : 19.14 (-3.53%)
COCO : 48.24 (-0.72%)
FIGS : 14.66 (+0.27%)
Novo Nordisk’s FDA-Approved GLP-1s Now Available With Hims & Hers

Starting today, eligible customers can access a broad assortment of treatment options, including the only FDA-approved GLP-1 weight loss pill

HIMS : 19.14 (-3.53%)
2 Healthcare Stocks to Target This Week and 1 That Underwhelm

2 Healthcare Stocks to Target This Week and 1 That Underwhelm

HIMS : 19.14 (-3.53%)
NVAX : 7.70 (-3.99%)
DXCM : 62.22 (-0.24%)
Hims & Hers Health Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Hims & Hers Health, Inc. - HIMS

NEW YORK and NEW ORLEANS , March 20, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti , LLC ("KSF"), announces...

HIMS : 19.14 (-3.53%)
1 Growth Stock with All-Star Potential and 2 That Underwhelm

1 Growth Stock with All-Star Potential and 2 That Underwhelm

HIMS : 19.14 (-3.53%)
CSGP : 39.95 (+0.81%)
SMTC : 82.65 (+3.26%)
MarketBeat Week in Review – 03/09 - 03/13

Stocks moved higher this week despite uncertainty over the Iran conflict and oil prices; economic indicators point to no change in interest rates next week

GOOGL : 295.77 (-0.54%)
NVDA : 177.39 (+0.93%)
AVGO : 314.55 (+0.34%)
TJX : 161.29 (-0.46%)
FCEL : 6.60 (+2.17%)
CVX : 198.97 (+0.79%)
HIMS : 19.14 (-3.53%)
NVO : 36.98 (+1.37%)
MTN : 131.13 (+2.29%)
HBAN : 15.79 (-0.57%)
UNF : 256.19 (+0.63%)
COST : 1,014.96 (+1.85%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Hims & Hers Health Inc. is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling medical care for numerous conditions related to mental health, sexual health, dermatology, primary care and more. Hims & Hers Health Inc., formerly known as Oaktree...

See More

Key Turning Points

3rd Resistance Point 20.25
2nd Resistance Point 19.88
1st Resistance Point 19.51
Last Price 19.14
1st Support Level 18.76
2nd Support Level 18.39
3rd Support Level 18.02

See More

52-Week High 70.43
Fibonacci 61.8% 48.77
Fibonacci 50% 42.08
Fibonacci 38.2% 35.40
Last Price 19.14
52-Week Low 13.74

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.